Paris-based healthtech firm that transforms unstructured biomedical data into benefit-risk predictions, has secured $7 million in a seed funding round led by The Moon Venture, as Vestbee was told.
- ArcaScience develops an AI platform that evaluates the benefits and risks of drugs by analyzing clinical, preclinical, and real-world patient data, including electronic health records, clinical trials, literature, and patient-reported outcomes.
- The platform has been applied to over 70,000 patients in chronic skin disease studies and is used by clinical operations and pharmacovigilance teams to derisk trials and optimize drug development.
- The company works with 10 pharmaceutical clients, including Sanofi, AstraZeneca, GSK, Takeda, ICON, and the Paris Brain Institute, and participates in a pan-European consortium on pediatric brain cancer involving institutions such as Institut Gustave Roussy, the Medical University of Vienna, and major pharma companies including Roche and Merck.
- During the COVID-19 pandemic, ArcaScience was selected by the French government to organize and deliver the complete scientific knowledge on the virus, and its platform has been validated in multiple scientific publications.
Details of the deal
- The seed funding round was led by French VC firm The Moon Venture, with support from Pléiade Venture, Plug&Play Ventures, Bpifrance, and AKKA Technologies.
“ArcaScience is solving a critical need in the pharmaceutical industry with a groundbreaking technological approach. We’ve seen remarkable market traction to date, and we believe they are ideally positioned to have a major impact in the pharma and patient care industries. This investment aligns with our strategy of supporting companies that are transforming entire industries through AI," said the team at The Moon Venture.
- ArcaScience will use the $7 million funding to accelerate its international expansion into the US and UK, launch its first patient-facing solution, and further develop its AI algorithms to optimize drug development, derisk clinical trials, and provide more precise benefit-risk assessments.
